



IMI 11th Call for proposals

The **Innovative Medicines Initiative (IMI)** has launched its **11th Call for proposals**, giving researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

IMI warmly encourages **small and medium-sized enterprises (SMEs)**, **patients' organisations**, **regulatory authorities**, **academic teams**, **industry**, **hospitals** and other organisations to form consortia and apply for participation in the new IMI projects.

IMI's 11th Call for proposals has eight topics:

- Applied public-private research enabling osteoarthritis clinical headway
- European platform for proof of concept for prevention in Alzheimer's Disease
- Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers
- **Zoonoses** anticipation and preparedness initiative
- Generation of research tools to translate genomic discoveries into drug discovery projects
- Ecorisk prediction

Topics under the New Drugs for Bad Bugs (ND4BB) programme on antimicrobial resistance:

- ND4BB Topic 6: Epidemiology research and development of novel systemic antibacterial molecules against **healthcare-associated infections** due to Gram-negative pathogens
- ND4BB Topic 7: Development of novel inhaled antibiotic regimens in patients with **cystic fibrosis** (CF) and patients with **non-CF bronchiectasis** (BE)

Find out more: www.imi.europa.eu/content/11th-call-2013-8

Sign up for the 11th Call topic webinars

■ View the schedule and register at www.imi.europa.eu/events/2013/12/03/imis-11th-call-webinars

Search for project partners

IMI's **Partner Search tool** allows people interested in applying for IMI funding to find potential project partners.

■ The tool is accessible via www.imi.europa.eu/content/partner-search

DEADLINE for submitting Expressions of Interest

→8 April 2014





Innovative Medicines Initiative

Why apply?

- Take part in patient-centric biomedical / pharmaceutical research
- Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others
- Obtain research funding
- Gain access to the databases, knowledge and infrastructures of consortium partners
- Boost the visibility and status of your organisation in Europe and globally and gain access to new markets

Improved IMI rules and procedures

- Simpler application procedures
- **Faster** time to grant
- Improved funding rules
- Easier accounting & reporting

Spread the word

IMI's Calls for proposals offer researchers across Europe a unique opportunity to participate in ground-breaking projects that aim to deliver tangible benefits for patients. Spread the word by **forwarding this flyer to your contacts and networks**.

■ You can also use the material at: www.imi.europa.eu/content/documents

About IMI

As the world's largest public-private partnership in drug research, IMI is revolutionising the way pharmaceutical research is performed, by offering a **new and unique model** for **public-private collaboration**.

Through its €2 billion research programme, IMI aims to speed up the discovery and development of safer and more effective drugs for patients, and to reinvigorate the biopharmaceutical sector in Europe.

The main goal of this unique and innovative funding scheme is to **improve tools and technologies** (such as biomarkers, imaging techniques, knowledge management platforms ...) that will enable the **faster and more efficient development** of safer and better drugs for patients.

The **research consortia** participating in IMI projects include SMEs, universities and other research organisations, hospitals, patient organisations, public authorities and large pharmaceutical companies. In addition to **research** projects, IMI supports **education and training projects**.

IMI receives €1 billion in funding from the European Commission. This amount is matched by in-kind contributions from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Stay in touch

■ Visit the IMI **website**: <u>www.imi.europa.eu</u>

Sign up to the IMI Newsletter: www.imi.europa.eu/content/subscribe-imi-newsletter

■ Follow us on **Twitter**: @IMI_JU

Join the Innovative Medicines Initiative group on LinkedIn

Questions? e-mail us: infodesk@imi.europa.eu

Your national IMI contact: www.imi.europa.eu/content/states-representatives-groups